報價延遲最少15分鐘:2025/08/11 05:57 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.19
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.02/-4.53
|
|
企業價值
653.61M
|
| 資產負債 |
|
每股賬面淨值
0.75
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
105.76M
|
|
每股收益
1.12
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/11 05:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenuefrom the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
